Top Markets
#1 Ontology Gas Ontology Gas +25.71%
#2 EXOD EXOD +22.08%
#3 Verus Coin Verus Coin +20.52%
#4 Derive Derive +18.82%
#5 ETHGas ETHGas +16.86%
#6 Status Status +15.56%
#7 Geodnet Geodnet +14.76%
#8 Pons Pons +11.68%
#9 Collect on Fanable Collect on Fanable +10.92%
#10 Curve DAO Curve DAO +10.67%
Coin of the day
Ontology Gas Ontology Gas
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Vicapsys Life Sciences, Inc. Vicapsys Life Sciences, Inc.

Vicapsys Life Sciences, Inc.

VICP
Classifica tra le azioni #25708
Vicapsys Life Sciences, Inc. is primarily focused on bringing its exclusive... Vicapsys Life Sciences, Inc. is primarily focused on bringing its exclusive VICAPSYN product to market, guiding it through development and commercialization. This product's intended application is within the field of transplantation, specifically for various transplant therapies and associated stem-cell uses. Additionally, the company is advancing the development of VYBRIN, a compound based on CXCL12. VYBRIN is being investigated for multiple purposes: preventing the formation of post-surgical adhesions following abdominal operations, coating implantable medical devices and other implants to inhibit fibrosis, and promoting wound healing, with a particular emphasis on diabetic ulcers. The firm, originally incorporated in 1997, transitioned its name from Phage Therapeutics International, Inc. to Vicapsys Life Sciences, Inc. in September 2017. Its operations are headquartered in Suwanee, Georgia.
Prezzo delle azioni
$1.45
Ultima sincronizzazione: 2026-08-19
Capitalizzazione di mercato
$46.94M
Variazione (1 giorno)
0.00%
Variazione (1 anno)
-18.08%
Paese
US
Scambia Vicapsys Life Sciences, Inc. (VICP)

Categoria

Healthcare
Ricavi di Vicapsys Life Sciences, Inc. (VICP)
Ricavi nel Aug 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Vicapsys Life Sciences, Inc., i ricavi attuali dell'azienda (TTM) sono pari a 0. Nel 2026, l'azienda ha registrato ricavi di 0 uguale a i ricavi dell'anno 2026, che erano pari a 0. I ricavi rappresentano l'importo totale generato dalla vendita di beni o servizi. A differenza degli utili, le spese non vengono detratte.
Storico dei ricavi per Vicapsys Life Sciences, Inc. da 2026 a 2026
Ricavi alla fine di ogni anno
Anno Ricavi Cambia
Non abbastanza dati per le date fornite.
Ricavi di aziende simili o concorrenti
Azienda Ricavi Differenza nei ricavi Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.70B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US